Altimmune PE Ratio, Dividend, Profit Margin

Altimmune, Inc. (ALT) published its most recent earnings results on May. 2023 for the quarter ended Mar. 2023.

An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Altimmune, Inc. (NASDAQ:ALT)'s trailing twelve month ROE is N/A.

It is sometimes helpful for shareholders to know how their investments are doing. Return on investment (ROI) for Altimmune, Inc. (ALT) is N/A. As ROI percentages rise, profits exceed costs, thus analysts consider such investments to be a general win.  In contrast, the Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Altimmune, Inc. (ALT) currently has a ROA of N/A Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.

ALT reported a profit margin of N/A in the last quarter ended Mar. 2023. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.

Although Altimmune, Inc. has not yet announced its next earnings date, it is expected to be, May. 11, 2023 based on last year's announcement date.

According to Altimmune, Inc. (ALT)'s current performance indicators, the Quick Ratio of 11.60 in the last reported quarter. The current ratio of ALT stands at 11.60 in the last reported quarterand a Debt/Eq ratio of 0.